context
stringlengths 21
24.6k
| category
stringclasses 2
values | entity
stringlengths 1
12
| entity_type
stringclasses 5
values | query
stringlengths 97
3.31k
| answer
stringlengths 12
168
|
|---|---|---|---|---|---|
On November 28, 2023, IQVIA Inc. (the “Issuer”), completed the issuance and sale of $ 1,250 million in gross proceeds of 6.250 % senior secured notes due 2029 (the “2029 Senior Secured Notes”). The 2029 Senior Secured Notes were issued pursuant to an Indenture, dated November 28, 2023, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the 2029 Senior Secured Notes and as collateral agent, and the Company and certain subsidiaries of the Issuer as guarantors. The net proceeds from the 2029 Senior Secured Notes offering were used to repay certain of the outstanding term loans under the Company’s senior secured credit facilities due in 2024 and in 2025, and to pay fees and expenses related to the 2029 Senior Secured Notes offering and the Amendment. | text | 1250 | monetaryItemType | text: <entity> 1250 </entity> <entity type> monetaryItemType </entity type> <context> On November 28, 2023, IQVIA Inc. (the “Issuer”), completed the issuance and sale of $ 1,250 million in gross proceeds of 6.250 % senior secured notes due 2029 (the “2029 Senior Secured Notes”). The 2029 Senior Secured Notes were issued pursuant to an Indenture, dated November 28, 2023, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the 2029 Senior Secured Notes and as collateral agent, and the Company and certain subsidiaries of the Issuer as guarantors. The net proceeds from the 2029 Senior Secured Notes offering were used to repay certain of the outstanding term loans under the Company’s senior secured credit facilities due in 2024 and in 2025, and to pay fees and expenses related to the 2029 Senior Secured Notes offering and the Amendment. </context> | us-gaap:DebtInstrumentCarryingAmount |
On November 28, 2023, IQVIA Inc. (the “Issuer”), completed the issuance and sale of $ 1,250 million in gross proceeds of 6.250 % senior secured notes due 2029 (the “2029 Senior Secured Notes”). The 2029 Senior Secured Notes were issued pursuant to an Indenture, dated November 28, 2023, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the 2029 Senior Secured Notes and as collateral agent, and the Company and certain subsidiaries of the Issuer as guarantors. The net proceeds from the 2029 Senior Secured Notes offering were used to repay certain of the outstanding term loans under the Company’s senior secured credit facilities due in 2024 and in 2025, and to pay fees and expenses related to the 2029 Senior Secured Notes offering and the Amendment. | text | 6.250 | percentItemType | text: <entity> 6.250 </entity> <entity type> percentItemType </entity type> <context> On November 28, 2023, IQVIA Inc. (the “Issuer”), completed the issuance and sale of $ 1,250 million in gross proceeds of 6.250 % senior secured notes due 2029 (the “2029 Senior Secured Notes”). The 2029 Senior Secured Notes were issued pursuant to an Indenture, dated November 28, 2023, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the 2029 Senior Secured Notes and as collateral agent, and the Company and certain subsidiaries of the Issuer as guarantors. The net proceeds from the 2029 Senior Secured Notes offering were used to repay certain of the outstanding term loans under the Company’s senior secured credit facilities due in 2024 and in 2025, and to pay fees and expenses related to the 2029 Senior Secured Notes offering and the Amendment. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
The 2029 Senior Secured Notes are secured obligations of the Company, will mature on February 1, 2029, unless earlier repurchased or redeemed in accordance with their terms, and bear interest at the rate of 6.250 % per year, with interest payable semi-annually on February 1 and August 1 of each year, beginning on February 1, 2024. The Company may redeem the 2029 Senior Secured Notes prior to January 1, 2029 subject to a customary make-whole premium, and thereafter subject to a redemption price equal to 100% of the principal amount thereof plus accrued and unpaid interest. | text | 6.250 | percentItemType | text: <entity> 6.250 </entity> <entity type> percentItemType </entity type> <context> The 2029 Senior Secured Notes are secured obligations of the Company, will mature on February 1, 2029, unless earlier repurchased or redeemed in accordance with their terms, and bear interest at the rate of 6.250 % per year, with interest payable semi-annually on February 1 and August 1 of each year, beginning on February 1, 2024. The Company may redeem the 2029 Senior Secured Notes prior to January 1, 2029 subject to a customary make-whole premium, and thereafter subject to a redemption price equal to 100% of the principal amount thereof plus accrued and unpaid interest. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
On May 23, 2023, IQVIA Inc. (the “Issuer”) completed the issuance and sale of $ 750 million in gross proceeds of 5.700 % senior secured notes due 2028 (the “2028 Senior Secured Notes”). The 2028 Senior Secured Notes were issued pursuant to an Indenture, dated May 23, 2023, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the 2028 Senior Secured Notes and as collateral agent, and the Company and certain subsidiaries of the Issuer as guarantors. The net proceeds from the 2028 Senior Secured Notes offering were used to repay existing borrowings under the Company’s revolving credit facility and to pay fees and expenses related to the 2028 Senior Secured Notes offering and offering of 2030 Senior Notes (as defined below). | text | 750 | monetaryItemType | text: <entity> 750 </entity> <entity type> monetaryItemType </entity type> <context> On May 23, 2023, IQVIA Inc. (the “Issuer”) completed the issuance and sale of $ 750 million in gross proceeds of 5.700 % senior secured notes due 2028 (the “2028 Senior Secured Notes”). The 2028 Senior Secured Notes were issued pursuant to an Indenture, dated May 23, 2023, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the 2028 Senior Secured Notes and as collateral agent, and the Company and certain subsidiaries of the Issuer as guarantors. The net proceeds from the 2028 Senior Secured Notes offering were used to repay existing borrowings under the Company’s revolving credit facility and to pay fees and expenses related to the 2028 Senior Secured Notes offering and offering of 2030 Senior Notes (as defined below). </context> | us-gaap:DebtInstrumentCarryingAmount |
On May 23, 2023, IQVIA Inc. (the “Issuer”) completed the issuance and sale of $ 750 million in gross proceeds of 5.700 % senior secured notes due 2028 (the “2028 Senior Secured Notes”). The 2028 Senior Secured Notes were issued pursuant to an Indenture, dated May 23, 2023, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the 2028 Senior Secured Notes and as collateral agent, and the Company and certain subsidiaries of the Issuer as guarantors. The net proceeds from the 2028 Senior Secured Notes offering were used to repay existing borrowings under the Company’s revolving credit facility and to pay fees and expenses related to the 2028 Senior Secured Notes offering and offering of 2030 Senior Notes (as defined below). | text | 5.700 | percentItemType | text: <entity> 5.700 </entity> <entity type> percentItemType </entity type> <context> On May 23, 2023, IQVIA Inc. (the “Issuer”) completed the issuance and sale of $ 750 million in gross proceeds of 5.700 % senior secured notes due 2028 (the “2028 Senior Secured Notes”). The 2028 Senior Secured Notes were issued pursuant to an Indenture, dated May 23, 2023, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the 2028 Senior Secured Notes and as collateral agent, and the Company and certain subsidiaries of the Issuer as guarantors. The net proceeds from the 2028 Senior Secured Notes offering were used to repay existing borrowings under the Company’s revolving credit facility and to pay fees and expenses related to the 2028 Senior Secured Notes offering and offering of 2030 Senior Notes (as defined below). </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
The 2028 Senior Secured Notes are secured obligations of the Company, will mature on May 15, 2028, unless earlier repurchased or redeemed in accordance with their terms, and bear interest at the rate of 5.700 % per year, with interest payable semi-annually on May 15 and November 15 of each year, beginning on November 15, 2023. The Company may redeem the 2028 Senior Secured Notes prior to April 15, 2028 subject to a customary make-whole premium, and thereafter subject to a redemption price equal to 100% of the principal amount thereof plus accrued and unpaid interest. | text | 5.700 | percentItemType | text: <entity> 5.700 </entity> <entity type> percentItemType </entity type> <context> The 2028 Senior Secured Notes are secured obligations of the Company, will mature on May 15, 2028, unless earlier repurchased or redeemed in accordance with their terms, and bear interest at the rate of 5.700 % per year, with interest payable semi-annually on May 15 and November 15 of each year, beginning on November 15, 2023. The Company may redeem the 2028 Senior Secured Notes prior to April 15, 2028 subject to a customary make-whole premium, and thereafter subject to a redemption price equal to 100% of the principal amount thereof plus accrued and unpaid interest. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
In February 2024, the Issuer completed an exchange offer in which it issued $ 1,250 million aggregate principal amount of 6.250 % Senior Secured Notes due 2029 registered under the Securities Act (the “2029 Registered Notes”) and $ 750 million aggregate principal amount of 5.700 % Senior Secured Notes due 2028 registered under the Securities Act (the “2028 Registered Notes” and, together with the 2029 Registered Notes, the 2029 Senior Secured Notes, and the 2028 Senior Secured Notes, the “Notes”) in exchange for the same principal amount and substantially identical terms of the 2029 Senior Secured Notes and 2028 Senior Secured Notes, respectively. | text | 1250 | monetaryItemType | text: <entity> 1250 </entity> <entity type> monetaryItemType </entity type> <context> In February 2024, the Issuer completed an exchange offer in which it issued $ 1,250 million aggregate principal amount of 6.250 % Senior Secured Notes due 2029 registered under the Securities Act (the “2029 Registered Notes”) and $ 750 million aggregate principal amount of 5.700 % Senior Secured Notes due 2028 registered under the Securities Act (the “2028 Registered Notes” and, together with the 2029 Registered Notes, the 2029 Senior Secured Notes, and the 2028 Senior Secured Notes, the “Notes”) in exchange for the same principal amount and substantially identical terms of the 2029 Senior Secured Notes and 2028 Senior Secured Notes, respectively. </context> | us-gaap:DebtInstrumentCarryingAmount |
In February 2024, the Issuer completed an exchange offer in which it issued $ 1,250 million aggregate principal amount of 6.250 % Senior Secured Notes due 2029 registered under the Securities Act (the “2029 Registered Notes”) and $ 750 million aggregate principal amount of 5.700 % Senior Secured Notes due 2028 registered under the Securities Act (the “2028 Registered Notes” and, together with the 2029 Registered Notes, the 2029 Senior Secured Notes, and the 2028 Senior Secured Notes, the “Notes”) in exchange for the same principal amount and substantially identical terms of the 2029 Senior Secured Notes and 2028 Senior Secured Notes, respectively. | text | 6.250 | percentItemType | text: <entity> 6.250 </entity> <entity type> percentItemType </entity type> <context> In February 2024, the Issuer completed an exchange offer in which it issued $ 1,250 million aggregate principal amount of 6.250 % Senior Secured Notes due 2029 registered under the Securities Act (the “2029 Registered Notes”) and $ 750 million aggregate principal amount of 5.700 % Senior Secured Notes due 2028 registered under the Securities Act (the “2028 Registered Notes” and, together with the 2029 Registered Notes, the 2029 Senior Secured Notes, and the 2028 Senior Secured Notes, the “Notes”) in exchange for the same principal amount and substantially identical terms of the 2029 Senior Secured Notes and 2028 Senior Secured Notes, respectively. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
In February 2024, the Issuer completed an exchange offer in which it issued $ 1,250 million aggregate principal amount of 6.250 % Senior Secured Notes due 2029 registered under the Securities Act (the “2029 Registered Notes”) and $ 750 million aggregate principal amount of 5.700 % Senior Secured Notes due 2028 registered under the Securities Act (the “2028 Registered Notes” and, together with the 2029 Registered Notes, the 2029 Senior Secured Notes, and the 2028 Senior Secured Notes, the “Notes”) in exchange for the same principal amount and substantially identical terms of the 2029 Senior Secured Notes and 2028 Senior Secured Notes, respectively. | text | 750 | monetaryItemType | text: <entity> 750 </entity> <entity type> monetaryItemType </entity type> <context> In February 2024, the Issuer completed an exchange offer in which it issued $ 1,250 million aggregate principal amount of 6.250 % Senior Secured Notes due 2029 registered under the Securities Act (the “2029 Registered Notes”) and $ 750 million aggregate principal amount of 5.700 % Senior Secured Notes due 2028 registered under the Securities Act (the “2028 Registered Notes” and, together with the 2029 Registered Notes, the 2029 Senior Secured Notes, and the 2028 Senior Secured Notes, the “Notes”) in exchange for the same principal amount and substantially identical terms of the 2029 Senior Secured Notes and 2028 Senior Secured Notes, respectively. </context> | us-gaap:DebtInstrumentCarryingAmount |
In February 2024, the Issuer completed an exchange offer in which it issued $ 1,250 million aggregate principal amount of 6.250 % Senior Secured Notes due 2029 registered under the Securities Act (the “2029 Registered Notes”) and $ 750 million aggregate principal amount of 5.700 % Senior Secured Notes due 2028 registered under the Securities Act (the “2028 Registered Notes” and, together with the 2029 Registered Notes, the 2029 Senior Secured Notes, and the 2028 Senior Secured Notes, the “Notes”) in exchange for the same principal amount and substantially identical terms of the 2029 Senior Secured Notes and 2028 Senior Secured Notes, respectively. | text | 5.700 | percentItemType | text: <entity> 5.700 </entity> <entity type> percentItemType </entity type> <context> In February 2024, the Issuer completed an exchange offer in which it issued $ 1,250 million aggregate principal amount of 6.250 % Senior Secured Notes due 2029 registered under the Securities Act (the “2029 Registered Notes”) and $ 750 million aggregate principal amount of 5.700 % Senior Secured Notes due 2028 registered under the Securities Act (the “2028 Registered Notes” and, together with the 2029 Registered Notes, the 2029 Senior Secured Notes, and the 2028 Senior Secured Notes, the “Notes”) in exchange for the same principal amount and substantially identical terms of the 2029 Senior Secured Notes and 2028 Senior Secured Notes, respectively. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
On May 23, 2023, IQVIA Inc. (the “Issuer”) completed the issuance and sale of $ 500 million in gross proceeds of 6.500 % senior notes due 2030 (the “2030 Senior Notes”). The 2030 Senior Notes were issued pursuant to an Indenture, dated May 23, 2023, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the 2030 Senior Notes, and certain subsidiaries of the Issuer as guarantors. The net proceeds from the 2030 Senior Notes offering were used to repay existing borrowings under the Company’s revolving credit facility, and to pay fees and expenses related to the 2030 Senior Notes offering and 2028 Senior Secured Notes offering. | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> On May 23, 2023, IQVIA Inc. (the “Issuer”) completed the issuance and sale of $ 500 million in gross proceeds of 6.500 % senior notes due 2030 (the “2030 Senior Notes”). The 2030 Senior Notes were issued pursuant to an Indenture, dated May 23, 2023, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the 2030 Senior Notes, and certain subsidiaries of the Issuer as guarantors. The net proceeds from the 2030 Senior Notes offering were used to repay existing borrowings under the Company’s revolving credit facility, and to pay fees and expenses related to the 2030 Senior Notes offering and 2028 Senior Secured Notes offering. </context> | us-gaap:DebtInstrumentCarryingAmount |
On May 23, 2023, IQVIA Inc. (the “Issuer”) completed the issuance and sale of $ 500 million in gross proceeds of 6.500 % senior notes due 2030 (the “2030 Senior Notes”). The 2030 Senior Notes were issued pursuant to an Indenture, dated May 23, 2023, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the 2030 Senior Notes, and certain subsidiaries of the Issuer as guarantors. The net proceeds from the 2030 Senior Notes offering were used to repay existing borrowings under the Company’s revolving credit facility, and to pay fees and expenses related to the 2030 Senior Notes offering and 2028 Senior Secured Notes offering. | text | 6.500 | percentItemType | text: <entity> 6.500 </entity> <entity type> percentItemType </entity type> <context> On May 23, 2023, IQVIA Inc. (the “Issuer”) completed the issuance and sale of $ 500 million in gross proceeds of 6.500 % senior notes due 2030 (the “2030 Senior Notes”). The 2030 Senior Notes were issued pursuant to an Indenture, dated May 23, 2023, among the Issuer, U.S. Bank Trust Company, National Association, as trustee of the 2030 Senior Notes, and certain subsidiaries of the Issuer as guarantors. The net proceeds from the 2030 Senior Notes offering were used to repay existing borrowings under the Company’s revolving credit facility, and to pay fees and expenses related to the 2030 Senior Notes offering and 2028 Senior Secured Notes offering. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
The 2030 Senior Notes are unsecured obligations of the Company, will mature on May 15, 2030, unless earlier repurchased or redeemed in accordance with their terms, and bear interest at the rate of 6.500 % per year, with interest payable semi-annually on May 15 and November 15 of each year, beginning on November 15, 2023. The Company may redeem the 2030 Senior Notes prior to their final stated maturity, subject to a customary make-whole premium, at any time prior to May 15, 2026 (subject to a customary “equity claw” redemption right) and thereafter subject to a redemption premium declining from 3.250 % to 0.000 %. | text | 6.500 | percentItemType | text: <entity> 6.500 </entity> <entity type> percentItemType </entity type> <context> The 2030 Senior Notes are unsecured obligations of the Company, will mature on May 15, 2030, unless earlier repurchased or redeemed in accordance with their terms, and bear interest at the rate of 6.500 % per year, with interest payable semi-annually on May 15 and November 15 of each year, beginning on November 15, 2023. The Company may redeem the 2030 Senior Notes prior to their final stated maturity, subject to a customary make-whole premium, at any time prior to May 15, 2026 (subject to a customary “equity claw” redemption right) and thereafter subject to a redemption premium declining from 3.250 % to 0.000 %. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
The 2030 Senior Notes are unsecured obligations of the Company, will mature on May 15, 2030, unless earlier repurchased or redeemed in accordance with their terms, and bear interest at the rate of 6.500 % per year, with interest payable semi-annually on May 15 and November 15 of each year, beginning on November 15, 2023. The Company may redeem the 2030 Senior Notes prior to their final stated maturity, subject to a customary make-whole premium, at any time prior to May 15, 2026 (subject to a customary “equity claw” redemption right) and thereafter subject to a redemption premium declining from 3.250 % to 0.000 %. | text | 3.250 | percentItemType | text: <entity> 3.250 </entity> <entity type> percentItemType </entity type> <context> The 2030 Senior Notes are unsecured obligations of the Company, will mature on May 15, 2030, unless earlier repurchased or redeemed in accordance with their terms, and bear interest at the rate of 6.500 % per year, with interest payable semi-annually on May 15 and November 15 of each year, beginning on November 15, 2023. The Company may redeem the 2030 Senior Notes prior to their final stated maturity, subject to a customary make-whole premium, at any time prior to May 15, 2026 (subject to a customary “equity claw” redemption right) and thereafter subject to a redemption premium declining from 3.250 % to 0.000 %. </context> | us-gaap:DebtInstrumentRedemptionPricePercentage |
The 2030 Senior Notes are unsecured obligations of the Company, will mature on May 15, 2030, unless earlier repurchased or redeemed in accordance with their terms, and bear interest at the rate of 6.500 % per year, with interest payable semi-annually on May 15 and November 15 of each year, beginning on November 15, 2023. The Company may redeem the 2030 Senior Notes prior to their final stated maturity, subject to a customary make-whole premium, at any time prior to May 15, 2026 (subject to a customary “equity claw” redemption right) and thereafter subject to a redemption premium declining from 3.250 % to 0.000 %. | text | 0.000 | percentItemType | text: <entity> 0.000 </entity> <entity type> percentItemType </entity type> <context> The 2030 Senior Notes are unsecured obligations of the Company, will mature on May 15, 2030, unless earlier repurchased or redeemed in accordance with their terms, and bear interest at the rate of 6.500 % per year, with interest payable semi-annually on May 15 and November 15 of each year, beginning on November 15, 2023. The Company may redeem the 2030 Senior Notes prior to their final stated maturity, subject to a customary make-whole premium, at any time prior to May 15, 2026 (subject to a customary “equity claw” redemption right) and thereafter subject to a redemption premium declining from 3.250 % to 0.000 %. </context> | us-gaap:DebtInstrumentRedemptionPricePercentage |
On October 1, 2024, the Company amended its receivables financing facility to extend the term of the $ 550 million facility to October 1, 2027. Under the receivables financing facility, certain of the Company's accounts receivable are sold on a non-recourse basis by certain of the Company's consolidated subsidiaries (each, an “Originator”) to another of the Company's consolidated subsidiaries, a bankruptcy-remote special purpose entity (the “SPE”). The SPE obtained a term loan and revolving loan commitment from a third-party lender, secured by liens on the assets of the SPE, to finance the purchase of the accounts receivable, which includes a $ 440 million term loan and a $ 110 million revolving loan commitment. As of December 31, 2024, no additional amounts of revolving loans were available under the receivables financing facility. The Company has guaranteed the performance of the obligations of existing and future subsidiaries that sell and service the accounts receivable under the receivables financing facility. The assets of the SPE are not available to satisfy any of the Company’s obligations or any obligations of its subsidiaries. As of December 31, 2024, approximately $ 1,609 million of the Company's trade accounts receivable and unbilled services were pledged as collateral to secure the facility. | text | 550 | monetaryItemType | text: <entity> 550 </entity> <entity type> monetaryItemType </entity type> <context> On October 1, 2024, the Company amended its receivables financing facility to extend the term of the $ 550 million facility to October 1, 2027. Under the receivables financing facility, certain of the Company's accounts receivable are sold on a non-recourse basis by certain of the Company's consolidated subsidiaries (each, an “Originator”) to another of the Company's consolidated subsidiaries, a bankruptcy-remote special purpose entity (the “SPE”). The SPE obtained a term loan and revolving loan commitment from a third-party lender, secured by liens on the assets of the SPE, to finance the purchase of the accounts receivable, which includes a $ 440 million term loan and a $ 110 million revolving loan commitment. As of December 31, 2024, no additional amounts of revolving loans were available under the receivables financing facility. The Company has guaranteed the performance of the obligations of existing and future subsidiaries that sell and service the accounts receivable under the receivables financing facility. The assets of the SPE are not available to satisfy any of the Company’s obligations or any obligations of its subsidiaries. As of December 31, 2024, approximately $ 1,609 million of the Company's trade accounts receivable and unbilled services were pledged as collateral to secure the facility. </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On October 1, 2024, the Company amended its receivables financing facility to extend the term of the $ 550 million facility to October 1, 2027. Under the receivables financing facility, certain of the Company's accounts receivable are sold on a non-recourse basis by certain of the Company's consolidated subsidiaries (each, an “Originator”) to another of the Company's consolidated subsidiaries, a bankruptcy-remote special purpose entity (the “SPE”). The SPE obtained a term loan and revolving loan commitment from a third-party lender, secured by liens on the assets of the SPE, to finance the purchase of the accounts receivable, which includes a $ 440 million term loan and a $ 110 million revolving loan commitment. As of December 31, 2024, no additional amounts of revolving loans were available under the receivables financing facility. The Company has guaranteed the performance of the obligations of existing and future subsidiaries that sell and service the accounts receivable under the receivables financing facility. The assets of the SPE are not available to satisfy any of the Company’s obligations or any obligations of its subsidiaries. As of December 31, 2024, approximately $ 1,609 million of the Company's trade accounts receivable and unbilled services were pledged as collateral to secure the facility. | text | 440 | monetaryItemType | text: <entity> 440 </entity> <entity type> monetaryItemType </entity type> <context> On October 1, 2024, the Company amended its receivables financing facility to extend the term of the $ 550 million facility to October 1, 2027. Under the receivables financing facility, certain of the Company's accounts receivable are sold on a non-recourse basis by certain of the Company's consolidated subsidiaries (each, an “Originator”) to another of the Company's consolidated subsidiaries, a bankruptcy-remote special purpose entity (the “SPE”). The SPE obtained a term loan and revolving loan commitment from a third-party lender, secured by liens on the assets of the SPE, to finance the purchase of the accounts receivable, which includes a $ 440 million term loan and a $ 110 million revolving loan commitment. As of December 31, 2024, no additional amounts of revolving loans were available under the receivables financing facility. The Company has guaranteed the performance of the obligations of existing and future subsidiaries that sell and service the accounts receivable under the receivables financing facility. The assets of the SPE are not available to satisfy any of the Company’s obligations or any obligations of its subsidiaries. As of December 31, 2024, approximately $ 1,609 million of the Company's trade accounts receivable and unbilled services were pledged as collateral to secure the facility. </context> | us-gaap:LineOfCredit |
On October 1, 2024, the Company amended its receivables financing facility to extend the term of the $ 550 million facility to October 1, 2027. Under the receivables financing facility, certain of the Company's accounts receivable are sold on a non-recourse basis by certain of the Company's consolidated subsidiaries (each, an “Originator”) to another of the Company's consolidated subsidiaries, a bankruptcy-remote special purpose entity (the “SPE”). The SPE obtained a term loan and revolving loan commitment from a third-party lender, secured by liens on the assets of the SPE, to finance the purchase of the accounts receivable, which includes a $ 440 million term loan and a $ 110 million revolving loan commitment. As of December 31, 2024, no additional amounts of revolving loans were available under the receivables financing facility. The Company has guaranteed the performance of the obligations of existing and future subsidiaries that sell and service the accounts receivable under the receivables financing facility. The assets of the SPE are not available to satisfy any of the Company’s obligations or any obligations of its subsidiaries. As of December 31, 2024, approximately $ 1,609 million of the Company's trade accounts receivable and unbilled services were pledged as collateral to secure the facility. | text | 110 | monetaryItemType | text: <entity> 110 </entity> <entity type> monetaryItemType </entity type> <context> On October 1, 2024, the Company amended its receivables financing facility to extend the term of the $ 550 million facility to October 1, 2027. Under the receivables financing facility, certain of the Company's accounts receivable are sold on a non-recourse basis by certain of the Company's consolidated subsidiaries (each, an “Originator”) to another of the Company's consolidated subsidiaries, a bankruptcy-remote special purpose entity (the “SPE”). The SPE obtained a term loan and revolving loan commitment from a third-party lender, secured by liens on the assets of the SPE, to finance the purchase of the accounts receivable, which includes a $ 440 million term loan and a $ 110 million revolving loan commitment. As of December 31, 2024, no additional amounts of revolving loans were available under the receivables financing facility. The Company has guaranteed the performance of the obligations of existing and future subsidiaries that sell and service the accounts receivable under the receivables financing facility. The assets of the SPE are not available to satisfy any of the Company’s obligations or any obligations of its subsidiaries. As of December 31, 2024, approximately $ 1,609 million of the Company's trade accounts receivable and unbilled services were pledged as collateral to secure the facility. </context> | us-gaap:LineOfCredit |
On January 10, 2017, Quintiles IMS Health Incorporated and IMS Software Services Ltd. (collectively “IQVIA Parties”), filed a lawsuit in the U.S. District Court for the District of New Jersey against Veeva Systems, Inc. (“Veeva”) alleging Veeva unlawfully used IQVIA Parties intellectual property to improve Veeva data offerings, to promote and market Veeva data offerings and to improve Veeva technology offerings. IQVIA Parties seek injunctive relief, appointment of a monitor, the award of compensatory and punitive damages and reimbursement of all litigation expenses, including reasonable attorneys’ fees and costs. On March 13, 2017, Veeva filed counterclaims alleging anticompetitive business practices in violation of the Sherman Act and state laws. Veeva claims damages in excess of $ 200 million, and is seeking punitive damages and litigation costs, including attorneys’ fees. The Company believes the counterclaims are without merit, rejects all counterclaims raised by Veeva and intends to vigorously defend IQVIA Parties’ position and pursue its claims against Veeva. Since the initial filings, the parties have filed additional litigations against each other, primarily concerning the use of IQVIA data with various other Veeva products. Trial has been continued from an early 2025 setting to a date to be determined by the Court. | text | 200 | monetaryItemType | text: <entity> 200 </entity> <entity type> monetaryItemType </entity type> <context> On January 10, 2017, Quintiles IMS Health Incorporated and IMS Software Services Ltd. (collectively “IQVIA Parties”), filed a lawsuit in the U.S. District Court for the District of New Jersey against Veeva Systems, Inc. (“Veeva”) alleging Veeva unlawfully used IQVIA Parties intellectual property to improve Veeva data offerings, to promote and market Veeva data offerings and to improve Veeva technology offerings. IQVIA Parties seek injunctive relief, appointment of a monitor, the award of compensatory and punitive damages and reimbursement of all litigation expenses, including reasonable attorneys’ fees and costs. On March 13, 2017, Veeva filed counterclaims alleging anticompetitive business practices in violation of the Sherman Act and state laws. Veeva claims damages in excess of $ 200 million, and is seeking punitive damages and litigation costs, including attorneys’ fees. The Company believes the counterclaims are without merit, rejects all counterclaims raised by Veeva and intends to vigorously defend IQVIA Parties’ position and pursue its claims against Veeva. Since the initial filings, the parties have filed additional litigations against each other, primarily concerning the use of IQVIA data with various other Veeva products. Trial has been continued from an early 2025 setting to a date to be determined by the Court. </context> | us-gaap:LossContingencyDamagesSoughtValue |
The Company is authorized to issue 1.0 million shares of preferred stock, $ 0.01 per share par value. No shares of preferred stock were issued and outstanding as of December 31, 2024 or 2023. | text | 1.0 | sharesItemType | text: <entity> 1.0 </entity> <entity type> sharesItemType </entity type> <context> The Company is authorized to issue 1.0 million shares of preferred stock, $ 0.01 per share par value. No shares of preferred stock were issued and outstanding as of December 31, 2024 or 2023. </context> | us-gaap:PreferredStockSharesAuthorized |
The Company is authorized to issue 1.0 million shares of preferred stock, $ 0.01 per share par value. No shares of preferred stock were issued and outstanding as of December 31, 2024 or 2023. | text | 0.01 | perShareItemType | text: <entity> 0.01 </entity> <entity type> perShareItemType </entity type> <context> The Company is authorized to issue 1.0 million shares of preferred stock, $ 0.01 per share par value. No shares of preferred stock were issued and outstanding as of December 31, 2024 or 2023. </context> | us-gaap:PreferredStockParOrStatedValuePerShare |
As of December 31, 2024, the Company had remaining authorization to repurchase up to $ 1,013 million of its common stock under the Repurchase Program. In addition, from time to time, the Company has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program. | text | 1013 | monetaryItemType | text: <entity> 1013 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had remaining authorization to repurchase up to $ 1,013 million of its common stock under the Repurchase Program. In addition, from time to time, the Company has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program. </context> | us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 |
The portion of goodwill deductible for income tax purposes was preliminarily assessed as $ 343 million and $ 379 million for the years ended December 31, 2024 and 2023, respectively. | text | 343 | monetaryItemType | text: <entity> 343 </entity> <entity type> monetaryItemType </entity type> <context> The portion of goodwill deductible for income tax purposes was preliminarily assessed as $ 343 million and $ 379 million for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount |
The portion of goodwill deductible for income tax purposes was preliminarily assessed as $ 343 million and $ 379 million for the years ended December 31, 2024 and 2023, respectively. | text | 379 | monetaryItemType | text: <entity> 379 </entity> <entity type> monetaryItemType </entity type> <context> The portion of goodwill deductible for income tax purposes was preliminarily assessed as $ 343 million and $ 379 million for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount |
The management approved plans resulted in $ 67 million, $ 84 million and $ 28 million of restructuring expense, net of reversals, which consisted primarily of severance and other exit-related costs in the years ended December 31, 2024, 2023 and 2022, respectively. | text | 67 | monetaryItemType | text: <entity> 67 </entity> <entity type> monetaryItemType </entity type> <context> The management approved plans resulted in $ 67 million, $ 84 million and $ 28 million of restructuring expense, net of reversals, which consisted primarily of severance and other exit-related costs in the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:RestructuringCharges |
The management approved plans resulted in $ 67 million, $ 84 million and $ 28 million of restructuring expense, net of reversals, which consisted primarily of severance and other exit-related costs in the years ended December 31, 2024, 2023 and 2022, respectively. | text | 84 | monetaryItemType | text: <entity> 84 </entity> <entity type> monetaryItemType </entity type> <context> The management approved plans resulted in $ 67 million, $ 84 million and $ 28 million of restructuring expense, net of reversals, which consisted primarily of severance and other exit-related costs in the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:RestructuringCharges |
The management approved plans resulted in $ 67 million, $ 84 million and $ 28 million of restructuring expense, net of reversals, which consisted primarily of severance and other exit-related costs in the years ended December 31, 2024, 2023 and 2022, respectively. | text | 28 | monetaryItemType | text: <entity> 28 </entity> <entity type> monetaryItemType </entity type> <context> The management approved plans resulted in $ 67 million, $ 84 million and $ 28 million of restructuring expense, net of reversals, which consisted primarily of severance and other exit-related costs in the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:RestructuringCharges |
The Company's effective income tax rate was 18.0 %, 6.9 %, and 19.1 % for the years ending December 31, 2024, 2023, and 2022, respectively. The Company's effective income tax rate for December 31, 2023, was favorably impacted due to the completion of an internal legal entity restructuring that resulted in a benefit of $ 125 million. Historically, the Company recorded deferred tax assets related to certain foreign tax credits, and a full valuation allowance in relation to these foreign tax credits was established as it was not expected the credits would be utilized prior to expiration. The Company now believes it is reasonably possible that these foreign tax credits will be utilized and therefore recorded a tax benefit of $ 64 million related to the valuation allowance release and establishing related uncertain tax positions. Additionally, due to the restructuring the Company also reversed a deferred tax liability of $ 61 million due to a basis difference that was recovered in a tax-free manner. The effective tax rate was also favorably impacted by a reversal of uncertain tax positions relating to tax credit carryforwards in the amount of $ 21 million due to an audit settlement. | text | 18.0 | percentItemType | text: <entity> 18.0 </entity> <entity type> percentItemType </entity type> <context> The Company's effective income tax rate was 18.0 %, 6.9 %, and 19.1 % for the years ending December 31, 2024, 2023, and 2022, respectively. The Company's effective income tax rate for December 31, 2023, was favorably impacted due to the completion of an internal legal entity restructuring that resulted in a benefit of $ 125 million. Historically, the Company recorded deferred tax assets related to certain foreign tax credits, and a full valuation allowance in relation to these foreign tax credits was established as it was not expected the credits would be utilized prior to expiration. The Company now believes it is reasonably possible that these foreign tax credits will be utilized and therefore recorded a tax benefit of $ 64 million related to the valuation allowance release and establishing related uncertain tax positions. Additionally, due to the restructuring the Company also reversed a deferred tax liability of $ 61 million due to a basis difference that was recovered in a tax-free manner. The effective tax rate was also favorably impacted by a reversal of uncertain tax positions relating to tax credit carryforwards in the amount of $ 21 million due to an audit settlement. </context> | us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent |
The Company's effective income tax rate was 18.0 %, 6.9 %, and 19.1 % for the years ending December 31, 2024, 2023, and 2022, respectively. The Company's effective income tax rate for December 31, 2023, was favorably impacted due to the completion of an internal legal entity restructuring that resulted in a benefit of $ 125 million. Historically, the Company recorded deferred tax assets related to certain foreign tax credits, and a full valuation allowance in relation to these foreign tax credits was established as it was not expected the credits would be utilized prior to expiration. The Company now believes it is reasonably possible that these foreign tax credits will be utilized and therefore recorded a tax benefit of $ 64 million related to the valuation allowance release and establishing related uncertain tax positions. Additionally, due to the restructuring the Company also reversed a deferred tax liability of $ 61 million due to a basis difference that was recovered in a tax-free manner. The effective tax rate was also favorably impacted by a reversal of uncertain tax positions relating to tax credit carryforwards in the amount of $ 21 million due to an audit settlement. | text | 6.9 | percentItemType | text: <entity> 6.9 </entity> <entity type> percentItemType </entity type> <context> The Company's effective income tax rate was 18.0 %, 6.9 %, and 19.1 % for the years ending December 31, 2024, 2023, and 2022, respectively. The Company's effective income tax rate for December 31, 2023, was favorably impacted due to the completion of an internal legal entity restructuring that resulted in a benefit of $ 125 million. Historically, the Company recorded deferred tax assets related to certain foreign tax credits, and a full valuation allowance in relation to these foreign tax credits was established as it was not expected the credits would be utilized prior to expiration. The Company now believes it is reasonably possible that these foreign tax credits will be utilized and therefore recorded a tax benefit of $ 64 million related to the valuation allowance release and establishing related uncertain tax positions. Additionally, due to the restructuring the Company also reversed a deferred tax liability of $ 61 million due to a basis difference that was recovered in a tax-free manner. The effective tax rate was also favorably impacted by a reversal of uncertain tax positions relating to tax credit carryforwards in the amount of $ 21 million due to an audit settlement. </context> | us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent |
The Company's effective income tax rate was 18.0 %, 6.9 %, and 19.1 % for the years ending December 31, 2024, 2023, and 2022, respectively. The Company's effective income tax rate for December 31, 2023, was favorably impacted due to the completion of an internal legal entity restructuring that resulted in a benefit of $ 125 million. Historically, the Company recorded deferred tax assets related to certain foreign tax credits, and a full valuation allowance in relation to these foreign tax credits was established as it was not expected the credits would be utilized prior to expiration. The Company now believes it is reasonably possible that these foreign tax credits will be utilized and therefore recorded a tax benefit of $ 64 million related to the valuation allowance release and establishing related uncertain tax positions. Additionally, due to the restructuring the Company also reversed a deferred tax liability of $ 61 million due to a basis difference that was recovered in a tax-free manner. The effective tax rate was also favorably impacted by a reversal of uncertain tax positions relating to tax credit carryforwards in the amount of $ 21 million due to an audit settlement. | text | 19.1 | percentItemType | text: <entity> 19.1 </entity> <entity type> percentItemType </entity type> <context> The Company's effective income tax rate was 18.0 %, 6.9 %, and 19.1 % for the years ending December 31, 2024, 2023, and 2022, respectively. The Company's effective income tax rate for December 31, 2023, was favorably impacted due to the completion of an internal legal entity restructuring that resulted in a benefit of $ 125 million. Historically, the Company recorded deferred tax assets related to certain foreign tax credits, and a full valuation allowance in relation to these foreign tax credits was established as it was not expected the credits would be utilized prior to expiration. The Company now believes it is reasonably possible that these foreign tax credits will be utilized and therefore recorded a tax benefit of $ 64 million related to the valuation allowance release and establishing related uncertain tax positions. Additionally, due to the restructuring the Company also reversed a deferred tax liability of $ 61 million due to a basis difference that was recovered in a tax-free manner. The effective tax rate was also favorably impacted by a reversal of uncertain tax positions relating to tax credit carryforwards in the amount of $ 21 million due to an audit settlement. </context> | us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent |
The Company's effective income tax rate was 18.0 %, 6.9 %, and 19.1 % for the years ending December 31, 2024, 2023, and 2022, respectively. The Company's effective income tax rate for December 31, 2023, was favorably impacted due to the completion of an internal legal entity restructuring that resulted in a benefit of $ 125 million. Historically, the Company recorded deferred tax assets related to certain foreign tax credits, and a full valuation allowance in relation to these foreign tax credits was established as it was not expected the credits would be utilized prior to expiration. The Company now believes it is reasonably possible that these foreign tax credits will be utilized and therefore recorded a tax benefit of $ 64 million related to the valuation allowance release and establishing related uncertain tax positions. Additionally, due to the restructuring the Company also reversed a deferred tax liability of $ 61 million due to a basis difference that was recovered in a tax-free manner. The effective tax rate was also favorably impacted by a reversal of uncertain tax positions relating to tax credit carryforwards in the amount of $ 21 million due to an audit settlement. | text | 21 | monetaryItemType | text: <entity> 21 </entity> <entity type> monetaryItemType </entity type> <context> The Company's effective income tax rate was 18.0 %, 6.9 %, and 19.1 % for the years ending December 31, 2024, 2023, and 2022, respectively. The Company's effective income tax rate for December 31, 2023, was favorably impacted due to the completion of an internal legal entity restructuring that resulted in a benefit of $ 125 million. Historically, the Company recorded deferred tax assets related to certain foreign tax credits, and a full valuation allowance in relation to these foreign tax credits was established as it was not expected the credits would be utilized prior to expiration. The Company now believes it is reasonably possible that these foreign tax credits will be utilized and therefore recorded a tax benefit of $ 64 million related to the valuation allowance release and establishing related uncertain tax positions. Additionally, due to the restructuring the Company also reversed a deferred tax liability of $ 61 million due to a basis difference that was recovered in a tax-free manner. The effective tax rate was also favorably impacted by a reversal of uncertain tax positions relating to tax credit carryforwards in the amount of $ 21 million due to an audit settlement. </context> | us-gaap:IncomeTaxReconciliationTaxSettlementsDomestic |
Undistributed earnings of the Company’s foreign subsidiaries amounted to approximately $ 5,117 million as of December 31, 2024. The Company does not consider any of its foreign earnings as indefinitely reinvested. | text | 5117 | monetaryItemType | text: <entity> 5117 </entity> <entity type> monetaryItemType </entity type> <context> Undistributed earnings of the Company’s foreign subsidiaries amounted to approximately $ 5,117 million as of December 31, 2024. The Company does not consider any of its foreign earnings as indefinitely reinvested. </context> | us-gaap:UndistributedEarningsOfForeignSubsidiaries |
In the year ended December 31, 2024, the Company increased its valuation allowance by $ 30 million to $ 196 million as of December 31, 2024 from $ 166 million as of December 31, 2023. On December 10, 2024, the US Department of Treasury published final regulations related to foreign currency gains and losses that are effective as of January 1, 2025. These regulations require computation of pre-transition foreign currency gain or loss to be included in the determination of future taxable income or loss. The valuation allowance increased primarily as a result of these regulations. We recorded a one-time, non-cash deferred tax benefit related to the pre-transition foreign currency losses in the current year that will be fully offset by a valuation allowance. | text | 30 | monetaryItemType | text: <entity> 30 </entity> <entity type> monetaryItemType </entity type> <context> In the year ended December 31, 2024, the Company increased its valuation allowance by $ 30 million to $ 196 million as of December 31, 2024 from $ 166 million as of December 31, 2023. On December 10, 2024, the US Department of Treasury published final regulations related to foreign currency gains and losses that are effective as of January 1, 2025. These regulations require computation of pre-transition foreign currency gain or loss to be included in the determination of future taxable income or loss. The valuation allowance increased primarily as a result of these regulations. We recorded a one-time, non-cash deferred tax benefit related to the pre-transition foreign currency losses in the current year that will be fully offset by a valuation allowance. </context> | us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease |
In the year ended December 31, 2024, the Company increased its valuation allowance by $ 30 million to $ 196 million as of December 31, 2024 from $ 166 million as of December 31, 2023. On December 10, 2024, the US Department of Treasury published final regulations related to foreign currency gains and losses that are effective as of January 1, 2025. These regulations require computation of pre-transition foreign currency gain or loss to be included in the determination of future taxable income or loss. The valuation allowance increased primarily as a result of these regulations. We recorded a one-time, non-cash deferred tax benefit related to the pre-transition foreign currency losses in the current year that will be fully offset by a valuation allowance. | text | 196 | monetaryItemType | text: <entity> 196 </entity> <entity type> monetaryItemType </entity type> <context> In the year ended December 31, 2024, the Company increased its valuation allowance by $ 30 million to $ 196 million as of December 31, 2024 from $ 166 million as of December 31, 2023. On December 10, 2024, the US Department of Treasury published final regulations related to foreign currency gains and losses that are effective as of January 1, 2025. These regulations require computation of pre-transition foreign currency gain or loss to be included in the determination of future taxable income or loss. The valuation allowance increased primarily as a result of these regulations. We recorded a one-time, non-cash deferred tax benefit related to the pre-transition foreign currency losses in the current year that will be fully offset by a valuation allowance. </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
In the year ended December 31, 2024, the Company increased its valuation allowance by $ 30 million to $ 196 million as of December 31, 2024 from $ 166 million as of December 31, 2023. On December 10, 2024, the US Department of Treasury published final regulations related to foreign currency gains and losses that are effective as of January 1, 2025. These regulations require computation of pre-transition foreign currency gain or loss to be included in the determination of future taxable income or loss. The valuation allowance increased primarily as a result of these regulations. We recorded a one-time, non-cash deferred tax benefit related to the pre-transition foreign currency losses in the current year that will be fully offset by a valuation allowance. | text | 166 | monetaryItemType | text: <entity> 166 </entity> <entity type> monetaryItemType </entity type> <context> In the year ended December 31, 2024, the Company increased its valuation allowance by $ 30 million to $ 196 million as of December 31, 2024 from $ 166 million as of December 31, 2023. On December 10, 2024, the US Department of Treasury published final regulations related to foreign currency gains and losses that are effective as of January 1, 2025. These regulations require computation of pre-transition foreign currency gain or loss to be included in the determination of future taxable income or loss. The valuation allowance increased primarily as a result of these regulations. We recorded a one-time, non-cash deferred tax benefit related to the pre-transition foreign currency losses in the current year that will be fully offset by a valuation allowance. </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
As of December 31, 2024, the Company had total gross unrecognized income tax benefits of $ 132 million associated with over 100 jurisdictions in which the Company conducts business that, if recognized, would reduce the Company’s effective income tax rate. | text | 132 | monetaryItemType | text: <entity> 132 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had total gross unrecognized income tax benefits of $ 132 million associated with over 100 jurisdictions in which the Company conducts business that, if recognized, would reduce the Company’s effective income tax rate. </context> | us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate |
The Company’s policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of income. In the years ended December 31, 2024, 2023 and 2022, the amount of interest and penalties recorded as an addition to income tax expense in the accompanying consolidated statements of income was $ 6 million, $ — million and $ 2 million, respectively. As of December 31, 2024, and 2023, the Company had accrued approximately $ 26 million and $ 20 million, respectively, of interest and penalties. | text | 26 | monetaryItemType | text: <entity> 26 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of income. In the years ended December 31, 2024, 2023 and 2022, the amount of interest and penalties recorded as an addition to income tax expense in the accompanying consolidated statements of income was $ 6 million, $ — million and $ 2 million, respectively. As of December 31, 2024, and 2023, the Company had accrued approximately $ 26 million and $ 20 million, respectively, of interest and penalties. </context> | us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued |
The Company’s policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of income. In the years ended December 31, 2024, 2023 and 2022, the amount of interest and penalties recorded as an addition to income tax expense in the accompanying consolidated statements of income was $ 6 million, $ — million and $ 2 million, respectively. As of December 31, 2024, and 2023, the Company had accrued approximately $ 26 million and $ 20 million, respectively, of interest and penalties. | text | 20 | monetaryItemType | text: <entity> 20 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of income. In the years ended December 31, 2024, 2023 and 2022, the amount of interest and penalties recorded as an addition to income tax expense in the accompanying consolidated statements of income was $ 6 million, $ — million and $ 2 million, respectively. As of December 31, 2024, and 2023, the Company had accrued approximately $ 26 million and $ 20 million, respectively, of interest and penalties. </context> | us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued |
The Company believes that it is reasonably possible that a decrease of up to $ 8 million in gross unrecognized income tax benefits for federal, state and foreign exposure items may be necessary within the next 12 months due to lapse of statutes of limitations or uncertain tax positions being effectively settled. The Company believes that it is reasonably possible that a decrease of up to $ 13 million in gross unrecognized income tax benefits for foreign items may be necessary within the next 12 months due to payments. For the remaining uncertain income tax positions, it is difficult at this time to estimate the timing of the resolution. | text | 8 | monetaryItemType | text: <entity> 8 </entity> <entity type> monetaryItemType </entity type> <context> The Company believes that it is reasonably possible that a decrease of up to $ 8 million in gross unrecognized income tax benefits for federal, state and foreign exposure items may be necessary within the next 12 months due to lapse of statutes of limitations or uncertain tax positions being effectively settled. The Company believes that it is reasonably possible that a decrease of up to $ 13 million in gross unrecognized income tax benefits for foreign items may be necessary within the next 12 months due to payments. For the remaining uncertain income tax positions, it is difficult at this time to estimate the timing of the resolution. </context> | us-gaap:UnrecognizedTaxBenefits |
The Company believes that it is reasonably possible that a decrease of up to $ 8 million in gross unrecognized income tax benefits for federal, state and foreign exposure items may be necessary within the next 12 months due to lapse of statutes of limitations or uncertain tax positions being effectively settled. The Company believes that it is reasonably possible that a decrease of up to $ 13 million in gross unrecognized income tax benefits for foreign items may be necessary within the next 12 months due to payments. For the remaining uncertain income tax positions, it is difficult at this time to estimate the timing of the resolution. | text | 13 | monetaryItemType | text: <entity> 13 </entity> <entity type> monetaryItemType </entity type> <context> The Company believes that it is reasonably possible that a decrease of up to $ 8 million in gross unrecognized income tax benefits for federal, state and foreign exposure items may be necessary within the next 12 months due to lapse of statutes of limitations or uncertain tax positions being effectively settled. The Company believes that it is reasonably possible that a decrease of up to $ 13 million in gross unrecognized income tax benefits for foreign items may be necessary within the next 12 months due to payments. For the remaining uncertain income tax positions, it is difficult at this time to estimate the timing of the resolution. </context> | us-gaap:UnrecognizedTaxBenefits |
The Company expects to contribute approximately $ 30 million in required contributions to its pension and postretirement benefit plans during 2025. The Company may make additional contributions into its pension plans in 2025 depending on, among other factors, how the funded status of those plans change or in order to meet minimum funding requirements as set forth in employee benefit and tax laws, plus additional amounts the Company may deem to be appropriate. | text | 30 | monetaryItemType | text: <entity> 30 </entity> <entity type> monetaryItemType </entity type> <context> The Company expects to contribute approximately $ 30 million in required contributions to its pension and postretirement benefit plans during 2025. The Company may make additional contributions into its pension plans in 2025 depending on, among other factors, how the funded status of those plans change or in order to meet minimum funding requirements as set forth in employee benefit and tax laws, plus additional amounts the Company may deem to be appropriate. </context> | us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear |
In the United States, the Company has a 401(k) plan under which the Company matches employee deferrals at varying percentages and specified limits of the employee’s salary. For the years ended December 31, 2024, 2023 and 2022, the Company expensed $ 80 million, $ 81 million and $ 74 million, respectively, related to matching contributions. | text | 80 | monetaryItemType | text: <entity> 80 </entity> <entity type> monetaryItemType </entity type> <context> In the United States, the Company has a 401(k) plan under which the Company matches employee deferrals at varying percentages and specified limits of the employee’s salary. For the years ended December 31, 2024, 2023 and 2022, the Company expensed $ 80 million, $ 81 million and $ 74 million, respectively, related to matching contributions. </context> | us-gaap:DefinedContributionPlanCostRecognized |
In the United States, the Company has a 401(k) plan under which the Company matches employee deferrals at varying percentages and specified limits of the employee’s salary. For the years ended December 31, 2024, 2023 and 2022, the Company expensed $ 80 million, $ 81 million and $ 74 million, respectively, related to matching contributions. | text | 81 | monetaryItemType | text: <entity> 81 </entity> <entity type> monetaryItemType </entity type> <context> In the United States, the Company has a 401(k) plan under which the Company matches employee deferrals at varying percentages and specified limits of the employee’s salary. For the years ended December 31, 2024, 2023 and 2022, the Company expensed $ 80 million, $ 81 million and $ 74 million, respectively, related to matching contributions. </context> | us-gaap:DefinedContributionPlanCostRecognized |
In the United States, the Company has a 401(k) plan under which the Company matches employee deferrals at varying percentages and specified limits of the employee’s salary. For the years ended December 31, 2024, 2023 and 2022, the Company expensed $ 80 million, $ 81 million and $ 74 million, respectively, related to matching contributions. | text | 74 | monetaryItemType | text: <entity> 74 </entity> <entity type> monetaryItemType </entity type> <context> In the United States, the Company has a 401(k) plan under which the Company matches employee deferrals at varying percentages and specified limits of the employee’s salary. For the years ended December 31, 2024, 2023 and 2022, the Company expensed $ 80 million, $ 81 million and $ 74 million, respectively, related to matching contributions. </context> | us-gaap:DefinedContributionPlanCostRecognized |
The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. | text | 206 | monetaryItemType | text: <entity> 206 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. </context> | us-gaap:ShareBasedCompensation |
The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. | text | 217 | monetaryItemType | text: <entity> 217 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. </context> | us-gaap:ShareBasedCompensation |
The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. | text | 194 | monetaryItemType | text: <entity> 194 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. </context> | us-gaap:ShareBasedCompensation |
The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. | text | 36 | monetaryItemType | text: <entity> 36 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. | text | 34 | monetaryItemType | text: <entity> 34 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. | text | 28 | monetaryItemType | text: <entity> 28 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. | text | 215 | monetaryItemType | text: <entity> 215 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation expense of $ 206 million, $ 217 million and $ 194 million in the years ended December 31, 2024, 2023 and 2022, respectively. Stock-based compensation expense is included in selling, general and administrative expenses on the accompanying consolidated statements of income. The associated future income tax benefit recognized was $ 36 million, $ 34 million and $ 28 million in the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, there was approximately $ 215 million of total unrecognized stock-based compensation expense related to outstanding non-vested stock-based compensation arrangements, which the Company expects to recognize over a weighted average period of 1.2 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
As of December 31, 2024, there were 7.6 million shares available for future grants under all of the Company’s stock incentive plans. | text | 7.6 | sharesItemType | text: <entity> 7.6 </entity> <entity type> sharesItemType </entity type> <context> As of December 31, 2024, there were 7.6 million shares available for future grants under all of the Company’s stock incentive plans. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
The weighted average fair value per share of SSRs granted in the year ended December 31, 2024 was $ 70.63 . The total intrinsic value of SSRs exercised was approximately $ 88 million, $ 51 million and $ 25 million in the years ended December 31, 2024, 2023 and 2022, respectively. | text | 70.63 | perShareItemType | text: <entity> 70.63 </entity> <entity type> perShareItemType </entity type> <context> The weighted average fair value per share of SSRs granted in the year ended December 31, 2024 was $ 70.63 . The total intrinsic value of SSRs exercised was approximately $ 88 million, $ 51 million and $ 25 million in the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The total intrinsic value of options exercised was approximately $ 15 million, $ 23 million and $ 9 million in the years ended December 31, 2024, 2023 and 2022, respectively. The Company received cash of approximately $ 5 million, $ 7 million and $ 2 million in 2024, 2023, and 2022, respectively, from options exercised. | text | 15 | monetaryItemType | text: <entity> 15 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of options exercised was approximately $ 15 million, $ 23 million and $ 9 million in the years ended December 31, 2024, 2023 and 2022, respectively. The Company received cash of approximately $ 5 million, $ 7 million and $ 2 million in 2024, 2023, and 2022, respectively, from options exercised. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The total intrinsic value of options exercised was approximately $ 15 million, $ 23 million and $ 9 million in the years ended December 31, 2024, 2023 and 2022, respectively. The Company received cash of approximately $ 5 million, $ 7 million and $ 2 million in 2024, 2023, and 2022, respectively, from options exercised. | text | 23 | monetaryItemType | text: <entity> 23 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of options exercised was approximately $ 15 million, $ 23 million and $ 9 million in the years ended December 31, 2024, 2023 and 2022, respectively. The Company received cash of approximately $ 5 million, $ 7 million and $ 2 million in 2024, 2023, and 2022, respectively, from options exercised. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The total intrinsic value of options exercised was approximately $ 15 million, $ 23 million and $ 9 million in the years ended December 31, 2024, 2023 and 2022, respectively. The Company received cash of approximately $ 5 million, $ 7 million and $ 2 million in 2024, 2023, and 2022, respectively, from options exercised. | text | 9 | monetaryItemType | text: <entity> 9 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of options exercised was approximately $ 15 million, $ 23 million and $ 9 million in the years ended December 31, 2024, 2023 and 2022, respectively. The Company received cash of approximately $ 5 million, $ 7 million and $ 2 million in 2024, 2023, and 2022, respectively, from options exercised. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The total intrinsic value of options exercised was approximately $ 15 million, $ 23 million and $ 9 million in the years ended December 31, 2024, 2023 and 2022, respectively. The Company received cash of approximately $ 5 million, $ 7 million and $ 2 million in 2024, 2023, and 2022, respectively, from options exercised. | text | 5 | monetaryItemType | text: <entity> 5 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of options exercised was approximately $ 15 million, $ 23 million and $ 9 million in the years ended December 31, 2024, 2023 and 2022, respectively. The Company received cash of approximately $ 5 million, $ 7 million and $ 2 million in 2024, 2023, and 2022, respectively, from options exercised. </context> | us-gaap:ProceedsFromStockOptionsExercised |
The total intrinsic value of options exercised was approximately $ 15 million, $ 23 million and $ 9 million in the years ended December 31, 2024, 2023 and 2022, respectively. The Company received cash of approximately $ 5 million, $ 7 million and $ 2 million in 2024, 2023, and 2022, respectively, from options exercised. | text | 7 | monetaryItemType | text: <entity> 7 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of options exercised was approximately $ 15 million, $ 23 million and $ 9 million in the years ended December 31, 2024, 2023 and 2022, respectively. The Company received cash of approximately $ 5 million, $ 7 million and $ 2 million in 2024, 2023, and 2022, respectively, from options exercised. </context> | us-gaap:ProceedsFromStockOptionsExercised |
The total intrinsic value of options exercised was approximately $ 15 million, $ 23 million and $ 9 million in the years ended December 31, 2024, 2023 and 2022, respectively. The Company received cash of approximately $ 5 million, $ 7 million and $ 2 million in 2024, 2023, and 2022, respectively, from options exercised. | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of options exercised was approximately $ 15 million, $ 23 million and $ 9 million in the years ended December 31, 2024, 2023 and 2022, respectively. The Company received cash of approximately $ 5 million, $ 7 million and $ 2 million in 2024, 2023, and 2022, respectively, from options exercised. </context> | us-gaap:ProceedsFromStockOptionsExercised |
The weighted average remaining contractual life of the options outstanding and exercisable as of December 31, 2024 is 1.0 years. The total aggregate intrinsic value of the exercisable stock options as of December 31, 2024 was approximately $ 11 million. | text | 11 | monetaryItemType | text: <entity> 11 </entity> <entity type> monetaryItemType </entity type> <context> The weighted average remaining contractual life of the options outstanding and exercisable as of December 31, 2024 is 1.0 years. The total aggregate intrinsic value of the exercisable stock options as of December 31, 2024 was approximately $ 11 million. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue |
As of December 31, 2024, there are 992,478 performance awards outstanding with an intrinsic value of approximately $ 195 million. | text | 992478 | sharesItemType | text: <entity> 992478 </entity> <entity type> sharesItemType </entity type> <context> As of December 31, 2024, there are 992,478 performance awards outstanding with an intrinsic value of approximately $ 195 million. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber |
As of December 31, 2024, there are 992,478 performance awards outstanding with an intrinsic value of approximately $ 195 million. | text | 195 | monetaryItemType | text: <entity> 195 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, there are 992,478 performance awards outstanding with an intrinsic value of approximately $ 195 million. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding |
The Company’s RSUs will settle in shares of the Company’s common stock within 30 days of the applicable vesting date. In general, RSUs granted to employees vest either (i) one-third per year beginning on the first anniversary of the grant date or (ii) 100 % at the end of the three-year period following the grant date. Members of the Company’s Board receive RSUs that are fully vested when granted. | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> The Company’s RSUs will settle in shares of the Company’s common stock within 30 days of the applicable vesting date. In general, RSUs granted to employees vest either (i) one-third per year beginning on the first anniversary of the grant date or (ii) 100 % at the end of the three-year period following the grant date. Members of the Company’s Board receive RSUs that are fully vested when granted. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage |
(1) Pursuant to the IQVIA Holdings Inc. Non-Employee Director Deferral Plan (the “Director Deferral Plan”), non-employee directors may elect to defer receipt of their cash and/or equity retainers. If a director elects to defer his or her retainer, he or she will instead be credited with that value in deferred shares under the Director Deferral Plan. Deferred shares become payable in Company common stock following a termination of the director’s Board service or the director’s death, or upon a change in control of the Company. The Company granted 6,482 deferred RSUs in 2024. | text | 6482 | sharesItemType | text: <entity> 6482 </entity> <entity type> sharesItemType </entity type> <context> (1) Pursuant to the IQVIA Holdings Inc. Non-Employee Director Deferral Plan (the “Director Deferral Plan”), non-employee directors may elect to defer receipt of their cash and/or equity retainers. If a director elects to defer his or her retainer, he or she will instead be credited with that value in deferred shares under the Director Deferral Plan. Deferred shares become payable in Company common stock following a termination of the director’s Board service or the director’s death, or upon a change in control of the Company. The Company granted 6,482 deferred RSUs in 2024. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
As of December 31, 2024, there are 1,000,328 RSUs outstanding with an intrinsic value of approximately $ 197 million. | text | 1000328 | sharesItemType | text: <entity> 1000328 </entity> <entity type> sharesItemType </entity type> <context> As of December 31, 2024, there are 1,000,328 RSUs outstanding with an intrinsic value of approximately $ 197 million. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber |
As of December 31, 2024, there are 1,000,328 RSUs outstanding with an intrinsic value of approximately $ 197 million. | text | 197 | monetaryItemType | text: <entity> 197 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, there are 1,000,328 RSUs outstanding with an intrinsic value of approximately $ 197 million. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding |
As of December 31, 2024, 2023 and 2022, the weighted average fair value per share of the CSRs outstanding was $ 109.83 , $ 152.17 and $ 147.41 , respectively. The Company paid approximately $ 3 million, $ 11 million and $ 1 million to settle exercised CSRs in the years ended December 31, 2024, 2023 and 2022, respectively. | text | 109.83 | perShareItemType | text: <entity> 109.83 </entity> <entity type> perShareItemType </entity type> <context> As of December 31, 2024, 2023 and 2022, the weighted average fair value per share of the CSRs outstanding was $ 109.83 , $ 152.17 and $ 147.41 , respectively. The Company paid approximately $ 3 million, $ 11 million and $ 1 million to settle exercised CSRs in the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
As of December 31, 2024, 2023 and 2022, the weighted average fair value per share of the CSRs outstanding was $ 109.83 , $ 152.17 and $ 147.41 , respectively. The Company paid approximately $ 3 million, $ 11 million and $ 1 million to settle exercised CSRs in the years ended December 31, 2024, 2023 and 2022, respectively. | text | 152.17 | perShareItemType | text: <entity> 152.17 </entity> <entity type> perShareItemType </entity type> <context> As of December 31, 2024, 2023 and 2022, the weighted average fair value per share of the CSRs outstanding was $ 109.83 , $ 152.17 and $ 147.41 , respectively. The Company paid approximately $ 3 million, $ 11 million and $ 1 million to settle exercised CSRs in the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
As of December 31, 2024, 2023 and 2022, the weighted average fair value per share of the CSRs outstanding was $ 109.83 , $ 152.17 and $ 147.41 , respectively. The Company paid approximately $ 3 million, $ 11 million and $ 1 million to settle exercised CSRs in the years ended December 31, 2024, 2023 and 2022, respectively. | text | 147.41 | perShareItemType | text: <entity> 147.41 </entity> <entity type> perShareItemType </entity type> <context> As of December 31, 2024, 2023 and 2022, the weighted average fair value per share of the CSRs outstanding was $ 109.83 , $ 152.17 and $ 147.41 , respectively. The Company paid approximately $ 3 million, $ 11 million and $ 1 million to settle exercised CSRs in the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
As of December 31, 2024, 2023 and 2022, the weighted average fair value per share of the CSRs outstanding was $ 109.83 , $ 152.17 and $ 147.41 , respectively. The Company paid approximately $ 3 million, $ 11 million and $ 1 million to settle exercised CSRs in the years ended December 31, 2024, 2023 and 2022, respectively. | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, 2023 and 2022, the weighted average fair value per share of the CSRs outstanding was $ 109.83 , $ 152.17 and $ 147.41 , respectively. The Company paid approximately $ 3 million, $ 11 million and $ 1 million to settle exercised CSRs in the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards |
As of December 31, 2024, 2023 and 2022, the weighted average fair value per share of the CSRs outstanding was $ 109.83 , $ 152.17 and $ 147.41 , respectively. The Company paid approximately $ 3 million, $ 11 million and $ 1 million to settle exercised CSRs in the years ended December 31, 2024, 2023 and 2022, respectively. | text | 11 | monetaryItemType | text: <entity> 11 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, 2023 and 2022, the weighted average fair value per share of the CSRs outstanding was $ 109.83 , $ 152.17 and $ 147.41 , respectively. The Company paid approximately $ 3 million, $ 11 million and $ 1 million to settle exercised CSRs in the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards |
As of December 31, 2024, 2023 and 2022, the weighted average fair value per share of the CSRs outstanding was $ 109.83 , $ 152.17 and $ 147.41 , respectively. The Company paid approximately $ 3 million, $ 11 million and $ 1 million to settle exercised CSRs in the years ended December 31, 2024, 2023 and 2022, respectively. | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, 2023 and 2022, the weighted average fair value per share of the CSRs outstanding was $ 109.83 , $ 152.17 and $ 147.41 , respectively. The Company paid approximately $ 3 million, $ 11 million and $ 1 million to settle exercised CSRs in the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards |
The Company’s cash settled RSUs (“Cash RSUs”) require the Company to settle in cash an amount equal to the fair value of the Company’s common stock on the vest date multiplied by the number of vested Cash RSUs. These awards vest either (i) 100 % at the end of the | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> The Company’s cash settled RSUs (“Cash RSUs”) require the Company to settle in cash an amount equal to the fair value of the Company’s common stock on the vest date multiplied by the number of vested Cash RSUs. These awards vest either (i) 100 % at the end of the </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage |
-year period following the date of grant, or (ii) one-third per year beginning on the first grant date anniversary. As of December 31, 2024, there are 5,808 Cash RSUs outstanding with an intrinsic value of approximately $ 1 million. | text | 5808 | sharesItemType | text: <entity> 5808 </entity> <entity type> sharesItemType </entity type> <context> -year period following the date of grant, or (ii) one-third per year beginning on the first grant date anniversary. As of December 31, 2024, there are 5,808 Cash RSUs outstanding with an intrinsic value of approximately $ 1 million. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber |
-year period following the date of grant, or (ii) one-third per year beginning on the first grant date anniversary. As of December 31, 2024, there are 5,808 Cash RSUs outstanding with an intrinsic value of approximately $ 1 million. | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> -year period following the date of grant, or (ii) one-third per year beginning on the first grant date anniversary. As of December 31, 2024, there are 5,808 Cash RSUs outstanding with an intrinsic value of approximately $ 1 million. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding |
During the year ended December 31, 2022, the Company entered into long term incentive award agreements with certain employees totaling a fixed monetary amount of $ 80 million to issue a variable number of common shares based on the fair market value when the awards vest on the third anniversary of the grant date. The Company accounts for the awards as liability-classified awards with the liability recorded in other current liabilities in the consolidated balance sheets as of December 31, 2024. The Company recorded approximately $ 26 million, $ 22 million and | text | 26 | monetaryItemType | text: <entity> 26 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, the Company entered into long term incentive award agreements with certain employees totaling a fixed monetary amount of $ 80 million to issue a variable number of common shares based on the fair market value when the awards vest on the third anniversary of the grant date. The Company accounts for the awards as liability-classified awards with the liability recorded in other current liabilities in the consolidated balance sheets as of December 31, 2024. The Company recorded approximately $ 26 million, $ 22 million and </context> | us-gaap:ShareBasedCompensation |
During the year ended December 31, 2022, the Company entered into long term incentive award agreements with certain employees totaling a fixed monetary amount of $ 80 million to issue a variable number of common shares based on the fair market value when the awards vest on the third anniversary of the grant date. The Company accounts for the awards as liability-classified awards with the liability recorded in other current liabilities in the consolidated balance sheets as of December 31, 2024. The Company recorded approximately $ 26 million, $ 22 million and | text | 22 | monetaryItemType | text: <entity> 22 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, the Company entered into long term incentive award agreements with certain employees totaling a fixed monetary amount of $ 80 million to issue a variable number of common shares based on the fair market value when the awards vest on the third anniversary of the grant date. The Company accounts for the awards as liability-classified awards with the liability recorded in other current liabilities in the consolidated balance sheets as of December 31, 2024. The Company recorded approximately $ 26 million, $ 22 million and </context> | us-gaap:ShareBasedCompensation |
The following table presents the Company’s operations by reportable segment. The Company is managed through three reportable segments, Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission critical information, technology solutions and real world insights and services to the Company’s life science clients. Research & Development Solutions, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. | text | three | integerItemType | text: <entity> three </entity> <entity type> integerItemType </entity type> <context> The following table presents the Company’s operations by reportable segment. The Company is managed through three reportable segments, Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission critical information, technology solutions and real world insights and services to the Company’s life science clients. Research & Development Solutions, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. </context> | us-gaap:NumberOfReportableSegments |
For the years ended December 31, 2024, 2023 and 2022 the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share because they are subject to performance conditions that have not been met at the end of the reporting period or the effect of including such stock-based awards in the computation would be anti-dilutive was 1.0 million, 1.0 million, and 0.5 million, million, respectively. | text | 1.0 | sharesItemType | text: <entity> 1.0 </entity> <entity type> sharesItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022 the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share because they are subject to performance conditions that have not been met at the end of the reporting period or the effect of including such stock-based awards in the computation would be anti-dilutive was 1.0 million, 1.0 million, and 0.5 million, million, respectively. </context> | us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
For the years ended December 31, 2024, 2023 and 2022 the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share because they are subject to performance conditions that have not been met at the end of the reporting period or the effect of including such stock-based awards in the computation would be anti-dilutive was 1.0 million, 1.0 million, and 0.5 million, million, respectively. | text | 0.5 | sharesItemType | text: <entity> 0.5 </entity> <entity type> sharesItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022 the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share because they are subject to performance conditions that have not been met at the end of the reporting period or the effect of including such stock-based awards in the computation would be anti-dilutive was 1.0 million, 1.0 million, and 0.5 million, million, respectively. </context> | us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
The Consolidated Financial Statements include all wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated. The Company participates in two joint ventures that have been consolidated in accordance with the consolidation accounting guidance. An analysis is performed to determine which reporting entity, if any, has a controlling financial interest in a variable interest entity (“VIE”) with a primarily qualitative analysis. The qualitative analysis is based on identifying the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance (the “power criterion”) and the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE (the “losses/benefit criterion”). The party that meets both these criteria is deemed to have a controlling financial interest. The party with the controlling financial interest is considered to be the primary beneficiary and as a result is required to consolidate the VIE. The Company has a 50 % interest in a joint venture in Hong Kong, established as Hubbell Asia Limited (“HAL”). The principal objective of HAL is to manage the operations of its wholly-owned manufacturing company in China. Under the accounting guidance, the Company is the primary beneficiary of HAL and as a result consolidates HAL. | text | 50 | percentItemType | text: <entity> 50 </entity> <entity type> percentItemType </entity type> <context> The Consolidated Financial Statements include all wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated. The Company participates in two joint ventures that have been consolidated in accordance with the consolidation accounting guidance. An analysis is performed to determine which reporting entity, if any, has a controlling financial interest in a variable interest entity (“VIE”) with a primarily qualitative analysis. The qualitative analysis is based on identifying the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance (the “power criterion”) and the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE (the “losses/benefit criterion”). The party that meets both these criteria is deemed to have a controlling financial interest. The party with the controlling financial interest is considered to be the primary beneficiary and as a result is required to consolidate the VIE. The Company has a 50 % interest in a joint venture in Hong Kong, established as Hubbell Asia Limited (“HAL”). The principal objective of HAL is to manage the operations of its wholly-owned manufacturing company in China. Under the accounting guidance, the Company is the primary beneficiary of HAL and as a result consolidates HAL. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
Inventories are stated at the lower of cost or market value. Approximately 45 % of total net inventory value is determined utilizing the last-in, first-out (LIFO) method of inventory accounting. The cost of foreign inventories and certain domestic inventories is determined utilizing average cost or first-in, first-out (FIFO) methods of inventory accounting. Reserves for excess and obsolete inventory are provided based on current assessments about future demand compared to on-hand quantities. | text | 45 | percentItemType | text: <entity> 45 </entity> <entity type> percentItemType </entity type> <context> Inventories are stated at the lower of cost or market value. Approximately 45 % of total net inventory value is determined utilizing the last-in, first-out (LIFO) method of inventory accounting. The cost of foreign inventories and certain domestic inventories is determined utilizing average cost or first-in, first-out (FIFO) methods of inventory accounting. Reserves for excess and obsolete inventory are provided based on current assessments about future demand compared to on-hand quantities. </context> | us-gaap:PercentageOfLIFOInventory |
Capitalized computer software costs, net of amortization, were $ 6.3 million and $ 5.8 million at December 31, 2024 and 2023, respectively. This balance is reflected in Other long-term assets in the Consolidated Balance Sheet. Capitalized computer software is for internal use and costs primarily consist of purchased materials, external services and salary costs for personnel dedicated to the projects. Software is amortized on a straight-line basis over appropriate periods, generally between three and five years . The Company recorded amortization expense of $ 3.6 million in 2024, $ 4.3 million in 2023 and $ 6.6 million in 2022 relating to capitalized computer software. | text | 6.3 | monetaryItemType | text: <entity> 6.3 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized computer software costs, net of amortization, were $ 6.3 million and $ 5.8 million at December 31, 2024 and 2023, respectively. This balance is reflected in Other long-term assets in the Consolidated Balance Sheet. Capitalized computer software is for internal use and costs primarily consist of purchased materials, external services and salary costs for personnel dedicated to the projects. Software is amortized on a straight-line basis over appropriate periods, generally between three and five years . The Company recorded amortization expense of $ 3.6 million in 2024, $ 4.3 million in 2023 and $ 6.6 million in 2022 relating to capitalized computer software. </context> | us-gaap:CapitalizedComputerSoftwareNet |
Capitalized computer software costs, net of amortization, were $ 6.3 million and $ 5.8 million at December 31, 2024 and 2023, respectively. This balance is reflected in Other long-term assets in the Consolidated Balance Sheet. Capitalized computer software is for internal use and costs primarily consist of purchased materials, external services and salary costs for personnel dedicated to the projects. Software is amortized on a straight-line basis over appropriate periods, generally between three and five years . The Company recorded amortization expense of $ 3.6 million in 2024, $ 4.3 million in 2023 and $ 6.6 million in 2022 relating to capitalized computer software. | text | 5.8 | monetaryItemType | text: <entity> 5.8 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized computer software costs, net of amortization, were $ 6.3 million and $ 5.8 million at December 31, 2024 and 2023, respectively. This balance is reflected in Other long-term assets in the Consolidated Balance Sheet. Capitalized computer software is for internal use and costs primarily consist of purchased materials, external services and salary costs for personnel dedicated to the projects. Software is amortized on a straight-line basis over appropriate periods, generally between three and five years . The Company recorded amortization expense of $ 3.6 million in 2024, $ 4.3 million in 2023 and $ 6.6 million in 2022 relating to capitalized computer software. </context> | us-gaap:CapitalizedComputerSoftwareNet |
Capitalized computer software costs, net of amortization, were $ 6.3 million and $ 5.8 million at December 31, 2024 and 2023, respectively. This balance is reflected in Other long-term assets in the Consolidated Balance Sheet. Capitalized computer software is for internal use and costs primarily consist of purchased materials, external services and salary costs for personnel dedicated to the projects. Software is amortized on a straight-line basis over appropriate periods, generally between three and five years . The Company recorded amortization expense of $ 3.6 million in 2024, $ 4.3 million in 2023 and $ 6.6 million in 2022 relating to capitalized computer software. | text | 3.6 | monetaryItemType | text: <entity> 3.6 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized computer software costs, net of amortization, were $ 6.3 million and $ 5.8 million at December 31, 2024 and 2023, respectively. This balance is reflected in Other long-term assets in the Consolidated Balance Sheet. Capitalized computer software is for internal use and costs primarily consist of purchased materials, external services and salary costs for personnel dedicated to the projects. Software is amortized on a straight-line basis over appropriate periods, generally between three and five years . The Company recorded amortization expense of $ 3.6 million in 2024, $ 4.3 million in 2023 and $ 6.6 million in 2022 relating to capitalized computer software. </context> | us-gaap:CapitalizedComputerSoftwareAmortization1 |
Capitalized computer software costs, net of amortization, were $ 6.3 million and $ 5.8 million at December 31, 2024 and 2023, respectively. This balance is reflected in Other long-term assets in the Consolidated Balance Sheet. Capitalized computer software is for internal use and costs primarily consist of purchased materials, external services and salary costs for personnel dedicated to the projects. Software is amortized on a straight-line basis over appropriate periods, generally between three and five years . The Company recorded amortization expense of $ 3.6 million in 2024, $ 4.3 million in 2023 and $ 6.6 million in 2022 relating to capitalized computer software. | text | 4.3 | monetaryItemType | text: <entity> 4.3 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized computer software costs, net of amortization, were $ 6.3 million and $ 5.8 million at December 31, 2024 and 2023, respectively. This balance is reflected in Other long-term assets in the Consolidated Balance Sheet. Capitalized computer software is for internal use and costs primarily consist of purchased materials, external services and salary costs for personnel dedicated to the projects. Software is amortized on a straight-line basis over appropriate periods, generally between three and five years . The Company recorded amortization expense of $ 3.6 million in 2024, $ 4.3 million in 2023 and $ 6.6 million in 2022 relating to capitalized computer software. </context> | us-gaap:CapitalizedComputerSoftwareAmortization1 |
Capitalized computer software costs, net of amortization, were $ 6.3 million and $ 5.8 million at December 31, 2024 and 2023, respectively. This balance is reflected in Other long-term assets in the Consolidated Balance Sheet. Capitalized computer software is for internal use and costs primarily consist of purchased materials, external services and salary costs for personnel dedicated to the projects. Software is amortized on a straight-line basis over appropriate periods, generally between three and five years . The Company recorded amortization expense of $ 3.6 million in 2024, $ 4.3 million in 2023 and $ 6.6 million in 2022 relating to capitalized computer software. | text | 6.6 | monetaryItemType | text: <entity> 6.6 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized computer software costs, net of amortization, were $ 6.3 million and $ 5.8 million at December 31, 2024 and 2023, respectively. This balance is reflected in Other long-term assets in the Consolidated Balance Sheet. Capitalized computer software is for internal use and costs primarily consist of purchased materials, external services and salary costs for personnel dedicated to the projects. Software is amortized on a straight-line basis over appropriate periods, generally between three and five years . The Company recorded amortization expense of $ 3.6 million in 2024, $ 4.3 million in 2023 and $ 6.6 million in 2022 relating to capitalized computer software. </context> | us-gaap:CapitalizedComputerSoftwareAmortization1 |
The Company has ongoing agreements with financial institutions to facilitate the processing of vendor payables (“Payment Services Arrangement”). Under these agreements, the Company pays the financial institution the stated amount of confirmed invoices from participating suppliers on their original maturity date. The terms of the vendor payables are not affected by vendors participating in these agreements. As a result, the amounts owed are presented as accounts payable in the Company’s Consolidated Balance Sheet, of which $ 101.9 million and $ 101.3 million was outstanding at December 31, 2024 and December 31, 2023, respectively. Either party may terminate the agreements with 30 days written notice. Cash flows under the program are reported in operating activities in the Company’s Consolidated Statement of Cash Flows. | text | 101.9 | monetaryItemType | text: <entity> 101.9 </entity> <entity type> monetaryItemType </entity type> <context> The Company has ongoing agreements with financial institutions to facilitate the processing of vendor payables (“Payment Services Arrangement”). Under these agreements, the Company pays the financial institution the stated amount of confirmed invoices from participating suppliers on their original maturity date. The terms of the vendor payables are not affected by vendors participating in these agreements. As a result, the amounts owed are presented as accounts payable in the Company’s Consolidated Balance Sheet, of which $ 101.9 million and $ 101.3 million was outstanding at December 31, 2024 and December 31, 2023, respectively. Either party may terminate the agreements with 30 days written notice. Cash flows under the program are reported in operating activities in the Company’s Consolidated Statement of Cash Flows. </context> | us-gaap:SupplierFinanceProgramObligationCurrent |
The Company has ongoing agreements with financial institutions to facilitate the processing of vendor payables (“Payment Services Arrangement”). Under these agreements, the Company pays the financial institution the stated amount of confirmed invoices from participating suppliers on their original maturity date. The terms of the vendor payables are not affected by vendors participating in these agreements. As a result, the amounts owed are presented as accounts payable in the Company’s Consolidated Balance Sheet, of which $ 101.9 million and $ 101.3 million was outstanding at December 31, 2024 and December 31, 2023, respectively. Either party may terminate the agreements with 30 days written notice. Cash flows under the program are reported in operating activities in the Company’s Consolidated Statement of Cash Flows. | text | 101.3 | monetaryItemType | text: <entity> 101.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company has ongoing agreements with financial institutions to facilitate the processing of vendor payables (“Payment Services Arrangement”). Under these agreements, the Company pays the financial institution the stated amount of confirmed invoices from participating suppliers on their original maturity date. The terms of the vendor payables are not affected by vendors participating in these agreements. As a result, the amounts owed are presented as accounts payable in the Company’s Consolidated Balance Sheet, of which $ 101.9 million and $ 101.3 million was outstanding at December 31, 2024 and December 31, 2023, respectively. Either party may terminate the agreements with 30 days written notice. Cash flows under the program are reported in operating activities in the Company’s Consolidated Statement of Cash Flows. </context> | us-gaap:SupplierFinanceProgramObligationCurrent |
In 2021, the Company entered into an agreement with a financial institution that allows participating suppliers to receive payment for outstanding invoices through a commercial purchasing card sponsored by a financial institution. The Company is required to settle such outstanding invoices through a consolidated payment to the financial institution 15 days after the commercial card billing cycle. The Company receives the benefit of extended payment terms and a rebate from the financial institution. Either party may terminate the agreement with 60 days written notice. The amount outstanding to the financial institution is presented as short-term debt in the Company’s Consolidated Balance Sheet, of which, $ 2.4 million and $ 2.0 million was outstanding at December 31, 2024 and December 31, 2023, respectively. Cash flows under the program are reported in financing activities in the Company’s Consolidated Statement of Cash Flows. | text | 2.4 | monetaryItemType | text: <entity> 2.4 </entity> <entity type> monetaryItemType </entity type> <context> In 2021, the Company entered into an agreement with a financial institution that allows participating suppliers to receive payment for outstanding invoices through a commercial purchasing card sponsored by a financial institution. The Company is required to settle such outstanding invoices through a consolidated payment to the financial institution 15 days after the commercial card billing cycle. The Company receives the benefit of extended payment terms and a rebate from the financial institution. Either party may terminate the agreement with 60 days written notice. The amount outstanding to the financial institution is presented as short-term debt in the Company’s Consolidated Balance Sheet, of which, $ 2.4 million and $ 2.0 million was outstanding at December 31, 2024 and December 31, 2023, respectively. Cash flows under the program are reported in financing activities in the Company’s Consolidated Statement of Cash Flows. </context> | us-gaap:SupplierFinanceProgramObligationCurrent |
In 2021, the Company entered into an agreement with a financial institution that allows participating suppliers to receive payment for outstanding invoices through a commercial purchasing card sponsored by a financial institution. The Company is required to settle such outstanding invoices through a consolidated payment to the financial institution 15 days after the commercial card billing cycle. The Company receives the benefit of extended payment terms and a rebate from the financial institution. Either party may terminate the agreement with 60 days written notice. The amount outstanding to the financial institution is presented as short-term debt in the Company’s Consolidated Balance Sheet, of which, $ 2.4 million and $ 2.0 million was outstanding at December 31, 2024 and December 31, 2023, respectively. Cash flows under the program are reported in financing activities in the Company’s Consolidated Statement of Cash Flows. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2021, the Company entered into an agreement with a financial institution that allows participating suppliers to receive payment for outstanding invoices through a commercial purchasing card sponsored by a financial institution. The Company is required to settle such outstanding invoices through a consolidated payment to the financial institution 15 days after the commercial card billing cycle. The Company receives the benefit of extended payment terms and a rebate from the financial institution. Either party may terminate the agreement with 60 days written notice. The amount outstanding to the financial institution is presented as short-term debt in the Company’s Consolidated Balance Sheet, of which, $ 2.4 million and $ 2.0 million was outstanding at December 31, 2024 and December 31, 2023, respectively. Cash flows under the program are reported in financing activities in the Company’s Consolidated Statement of Cash Flows. </context> | us-gaap:SupplierFinanceProgramObligationCurrent |
On February 1, 2022, the Company completed the sale of the C&I Lighting business to GE Current, a Daintree Company, for total net cash consideration of $ 332.8 million. We have concluded the divestiture of this business represents a strategic shift that will have a major effect on our operations and financial results, and as a result, is reported as a discontinued operation in our Consolidated Financial Statements for all periods presented. The C&I Lighting business was previously included in the Electrical Solutions segment. | text | 332.8 | monetaryItemType | text: <entity> 332.8 </entity> <entity type> monetaryItemType </entity type> <context> On February 1, 2022, the Company completed the sale of the C&I Lighting business to GE Current, a Daintree Company, for total net cash consideration of $ 332.8 million. We have concluded the divestiture of this business represents a strategic shift that will have a major effect on our operations and financial results, and as a result, is reported as a discontinued operation in our Consolidated Financial Statements for all periods presented. The C&I Lighting business was previously included in the Electrical Solutions segment. </context> | us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested |
Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. | text | 148.0 | monetaryItemType | text: <entity> 148.0 </entity> <entity type> monetaryItemType </entity type> <context> Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. </context> | us-gaap:ContractWithCustomerLiability |
Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. | text | 118.6 | monetaryItemType | text: <entity> 118.6 </entity> <entity type> monetaryItemType </entity type> <context> Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. </context> | us-gaap:ContractWithCustomerLiability |
Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. | text | 29.4 | monetaryItemType | text: <entity> 29.4 </entity> <entity type> monetaryItemType </entity type> <context> Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. </context> | us-gaap:IncreaseDecreaseInContractWithCustomerLiability |
Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. | text | 108.3 | monetaryItemType | text: <entity> 108.3 </entity> <entity type> monetaryItemType </entity type> <context> Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. </context> | us-gaap:IncreaseDecreaseInDeferredCharges |
Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. | text | 78.9 | monetaryItemType | text: <entity> 78.9 </entity> <entity type> monetaryItemType </entity type> <context> Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. </context> | us-gaap:ContractWithCustomerLiabilityRevenueRecognized |
Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. | text | 38.0 | monetaryItemType | text: <entity> 38.0 </entity> <entity type> monetaryItemType </entity type> <context> Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. </context> | us-gaap:ContractWithCustomerAssetNetCurrent |
Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. | text | 41.6 | monetaryItemType | text: <entity> 41.6 </entity> <entity type> monetaryItemType </entity type> <context> Contract liabilities were $ 148.0 million as of December 31, 2024 compared to $ 118.6 million as of December 31, 2023. The $ 29.4 million increase in our contract liabilities balance was primarily due to a $ 108.3 million net increase in current year deferrals primarily due to timing of advance payments on certain orders, partially offset by the recognition of $ 78.9 million in revenue related to amounts that were recorded in contract liabilities at January 1, 2024. The ending balance of contract assets was $ 38.0 million and $ 41.6 million as of December 31, 2024, and December 31, 2023, respectively, which primarily relates to performance obligations satisfied prior to payment for Systems Control that are recorded in Other current assets in the Consolidated Balance Sheets. Impairment losses recognized on our receivables and contract assets were immaterial in the twelve months ended December 31, 2024. See Note 1 – Significant Accounting Policies in the Notes to Consolidated Financial Statements for additional information. </context> | us-gaap:ContractWithCustomerAssetNetCurrent |
The Company has elected the practical expedient to disclose only the value of unsatisfied performance obligations for contracts with an original expected length greater than one year. As of December 31, 2024, the Company had approximately $ 70 million of unsatisfied performance obligations for contracts with an original expected length of greater than one year, primarily relating to long-term contracts of the Aclara business (within the Utility Solutions segment) to deliver and install meters, metering communications and grid monitoring sensor technology. The Company expects that a majority of the unsatisfied performance obligations will be completed and recognized over the next 2 years. | text | 70 | monetaryItemType | text: <entity> 70 </entity> <entity type> monetaryItemType </entity type> <context> The Company has elected the practical expedient to disclose only the value of unsatisfied performance obligations for contracts with an original expected length greater than one year. As of December 31, 2024, the Company had approximately $ 70 million of unsatisfied performance obligations for contracts with an original expected length of greater than one year, primarily relating to long-term contracts of the Aclara business (within the Utility Solutions segment) to deliver and install meters, metering communications and grid monitoring sensor technology. The Company expects that a majority of the unsatisfied performance obligations will be completed and recognized over the next 2 years. </context> | us-gaap:RevenueRemainingPerformanceObligation |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.